Tilray rises after reporting earnings, revenue beat
Tilray’s biggest areas of revenue growth have been its alcohol business and its international market.
Tilray rose in after-hours trading after it reported earnings results that beat Wall Street expectations, its first earnings report since President Trump signed an executive order directing regulators to reclassify marijuana as a less dangerous drug.
Tilray reported a loss per share of $0.02, compared to the $0.21 per-share loss analysts polled by FactSet were expecting. The company also reported $217.5 million in sales for the quarter ended November 30, higher than the $210.9 million the Street was penciling in.
The stock rose more than 5% in after-hours trading after the report came out. It’s up 54% over the past six months.
Tilray’s biggest areas of revenue growth have been its alcohol business and its international market. The company sold $20 million through its international segment, up from $14.8 million in the same period last year.
On December 18, Trump signed an executive order directing the attorney general to expedite the process of changing cannabis from a Schedule I drug, like heroin and LSD, to a Schedule III drug, like testosterone. The move would instantly make US cannabis companies more profitable by reducing their high tax burden.
Tilray does not sell adult-use cannabis in the US but still got a lift in its stock price amid the news, as it could potentially pave the way for the company to enter the market.
“As the U.S. regulatory landscape progresses, Tilray is prepared to leverage its experience to play a key role in building a responsible, research-oriented national medical cannabis industry,” Tilray CEO Irwin D. Simon said in a statement.
